Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Moataz Reda"'
Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
Autor:
Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, Natnaree Siriwon, Ruijie Wang, Husam Y. Zaidan, Daniel S. Bejan, Sherif Reda, Ngoc Ha Hoang, Noah A. Crumrine, Justin P. C. Rehwaldt, Akash Bindal, Gordon B. Mills, Joe W. Gray, Wassana Yantasee
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Only a minority of patients with non-small cell lung cancer (NSCLC) respond to immune checkpoint inhibitors. Here the authors design a nanosystem for the co-delivery of a PLK1 inhibitor and PD-L1 antibody, showing anti-tumor immune responses in precl
Externí odkaz:
https://doaj.org/article/47471679aa7f42218b940fed0ac3e8d9
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198141 (2018)
Intrinsic and acquired resistance to current HER2 targeted therapies remains a challenge in clinics. We have developed a therapeutic HER2 siRNA delivered using mesoporous silica nanoparticles modified with polymers and conjugated with HER2 targeting
Externí odkaz:
https://doaj.org/article/9858008292274bf0a788e0ebf3769ece
Autor:
Worapol Ngamcherdtrakul, Thanapon Sangvanich, Shaun Goodyear, Moataz Reda, Shenda Gu, David J. Castro, Primana Punnakitikashem, Wassana Yantasee
Publikováno v:
Bioengineering, Vol 6, Iss 1, p 23 (2019)
Multiparametric and high-content protein analysis of single cells or tissues cannot be accomplished with the currently available flow cytometry or imaging techniques utilizing fluorophore-labelled antibodies, because the number of spectrally resolvab
Externí odkaz:
https://doaj.org/article/0857a65cfdca4c5ba27f907408d6a03e
Autor:
Wassana Yantasee, Joe W. Gray, Thanapon Sangvanich, David J. Castro, Moataz Reda, Shenda Gu, Worapol Ngamcherdtrakul, Jingga Morry
Supplementary Figure S1: Mesoporous silica-based nanoconstruct for targeted delivery of siRNA; Supplementary Figure S2: Screening of siPLK1 by mRNA knockdown and viability; Supplementary Figure S3: ROS intensity and NOX1-5 mRNA levels of TNBC cell li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44515c048beddf613d9efceaae4da2ee
https://doi.org/10.1158/1535-7163.22508410.v1
https://doi.org/10.1158/1535-7163.22508410.v1
Autor:
Wassana Yantasee, Joe W. Gray, Thanapon Sangvanich, David J. Castro, Moataz Reda, Shenda Gu, Worapol Ngamcherdtrakul, Jingga Morry
Detailed description of the methods used in the manuscript.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::226f08dd059acacaf8f8e4085cd4ec59
https://doi.org/10.1158/1535-7163.22508407
https://doi.org/10.1158/1535-7163.22508407
Autor:
Moataz Reda, Worapol Ngamcherdtrakul, Ruijie Wang, Noah Crumrine, Cole Baker, Alyssa Wallstrum, Jeremy Saito, Natalie White, Wassana Yantasee
Publikováno v:
Cancer Research. 83:5119-5119
Given the complexity of cancer, it is becoming apparent that combination therapy - in which complementary biological pathways are simultaneously targeted - is required to achieve clinically meaningful responses. To that end, PDX Pharma, in collaborat
Autor:
Worapol Ngamcherdtrakul, Moataz Reda, Cole Baker, Noah Crumrine, Ruijie Wang, Alyssa Wallstrum, Natalie White, Jeremy Saito, Husam Zaidan, Justin Rehwaldt, Molly Nelson, Joe Gray, Wassana Yantasee
Publikováno v:
Cancer Research. 83:3229-3229
Immune checkpoint inhibitors (ICIs) have provided long-lasting response but only in a small subset of cancer patients. To address this shortcoming, we developed a nanotherapeutic (AIRISE-02) that can manipulate both cancer cells and immunosuppressive
Autor:
Moataz Reda, Worapol Ngamcherdtrakul, Molly Nelson, Natnaree Siriwon, Ruijie Wang, Husam Zaidan, Daniel Bejan, Sherif Reda, Ngoc Hoang, Noah Crumrine, Justin Rehwaldt, Akash Bindal, Gordon Mills, Joe Gray, Wassana Yantasee
Immune checkpoint inhibitors (ICIs) targeting PD-L1 and PD-1 have improved survival in a subset of patients with advanced non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients respond to ICIs, highlighting the need for superi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7b222327f6a2cb3dd07e32112d0eca4
https://doi.org/10.21203/rs.3.rs-142908/v2
https://doi.org/10.21203/rs.3.rs-142908/v2
Autor:
Worapol Ngamcherdtrakul, Daniel S. Bejan, William Cruz‐Muñoz, Moataz Reda, Husam Y. Zaidan, Natnaree Siriwon, Suphalak Marshall, Ruijie Wang, Molly A. Nelson, Justin P. C. Rehwaldt, Joe W. Gray, Kullervo Hynynen, Wassana Yantasee
Publikováno v:
Small
The first-line treatment of advanced and metastatic human epidermal growth factor receptor type 2 (HER2+) breast cancer requires two HER2-targeting antibodies (trastuzumab and pertuzumab) and a taxane (docetaxel or paclitaxel). The three-drug regimen
Autor:
Ngoc Ha Hoang, Amanda W. Lund, Wassana Yantasee, Ruijie Wang, Shiuh Wen Luoh, Gordon B. Mills, Sancy A. Leachman, Worapol Ngamcherdtrakul, Joe W. Gray, Molly A. Nelson, Husam Y. Zaidan, Daniel S. Bejan, Moataz Reda, Ryan S. Lane
Publikováno v:
Adv Mater
The success of immunotherapy with immune checkpoint inhibitors (ICIs) in a subset of individuals has been very exciting. However, in many cancers, responses to current ICIs are modest and are seen only in a small subsets of patients. Herein, a widely
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::024b3bc7b166573fe36392d8a42ffd95
https://europepmc.org/articles/PMC8424660/
https://europepmc.org/articles/PMC8424660/